Anthropic wants to develop its own drugs
Anthropic has launched Claude Science, a new AI workbench designed to assist researchers with data analysis and visualization. The company also announced plans to develop its own pharmaceutical treatments, specifically targeting neglected diseases.
Why it matters
This marks a significant shift for frontier AI companies moving from providing software tools to becoming active participants in drug discovery and development.
At the event “The Briefing: AI for Science” earlier this week, Anthropic announced Claude Science, a new “AI workbench for scientists” that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding tools and powerful AI models, framed the launch around what it says is AI’s potential to “dramatically accelerate the pace of scientific discovery and the development of healthcare interventions,” and touted a long list of biotech and pharma customers already using Claude.
The article reports on corporate announcements and industry trends without taking a stance on the efficacy or ethics of the move.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in